ANCA-Associated Vasculitis

Avacopan in Older Adults with ANCA-Associated Vasculitis: Efficacy and Safety Confirmed in ADVOCATE Post Hoc Analysis

By MedXY 10/23/2025

This post hoc analysis of the ADVOCATE trial demonstrates that avacopan is effective and safe for treating ANCA-associated vasculitis in patients aged 65 and older, achieving sustained remission with reduced glucocorticoid exposure and toxicity compared to prednisone taper.

Nephrology news Rheumatology

Avacopan Combined with Cyclophosphamide in ANCA-Associated Vasculitis: A Safer and Effective Alternative to Prednisone Taper

By MedXY 10/23/2025

Avacopan, a complement C5a receptor inhibitor, shows comparable remission rates to prednisone taper in ANCA-associated vasculitis patients receiving cyclophosphamide, with benefits of lower relapse, improved kidney function, and reduced glucocorticoid toxicity.

Nephrology news Rheumatology

Real-World Effectiveness of Rituximab and Cyclophosphamide in Severe ANCA-Associated Vasculitis: Insights from J-CANVAS

By MedXY 10/23/2025

A comprehensive review of a Japanese cohort study assessing rituximab and cyclophosphamide efficacy in severe microscopic polyangiitis and GPA, highlighting clinical implications.